This invention relates to a group of genes associated with
gestational hypertension, a method for predicting
gestational hypertension in early
pregnancy using these genes, and related applications. Specifically, this invention obtains transcript
start site feature values from at least one of the following genes from the cfDNA sample of a pregnant woman: LOC124902572, EEF1A1P16, LOC105369767, GOLM2, CDRT7, MEIS3, and LOC105376108. These transcript
start site feature values are then input into a prediction model, and the output results are used to determine the risk of
gestational hypertension. The number of sequences in the transcript
start site region after correction based on the transcript start site feature values is also considered. The prediction model obtained by this invention can effectively and robustly predict the risk of gestational hypertension (including
preeclampsia) in early
pregnancy, assisting doctors in early
pregnancy intervention and reducing the risk of gestational hypertension.